Skip to main content
Image
Emma Börgeson
Photo: Johan Wingborg
Breadcrumb

Emma Börgeson Group

Research group
Pågående forskning
Project owner
University of Gothenburg

Short description

Emma Börgeson, PhD, Assistant Professor in Medicine.

About Börgeson Lab

The Börgeson lab is a translational research team, investigating the underlying disease mechanisms of obesity and cardiometabolic disease, with a special interest in inflammatory resolution.

Inflammation is a key driver of obesity-induced cardiometabolic pathophysiology and consists of two phases: an initial acute phase followed by a resolving phase. The latter is actively regulated by specialized pro-resolving lipid mediators (SPMs). Lipoxins are one group of SPMs that act through defined receptors to promote the resolution of inflammation.

The overall aim of the research is to investigate and harness the therapeutic potential of lipoxins. Her studies suggest that treatment with lipoxins attenuates obesity-induced adipose inflammation and subsequent development of systemic disease (Börgeson et al, Cell Metabolism, 2015). Her lab is currently investigating the underlying mechanisms that mediate this protection, and whether their results from preclinical models can be translated to human pathophysiology.

The team combines experimental studies with clinical basic research to address their hypothesis in a translational manner. The Börgeson lab uses ex vivo cultures of patient tissue biopsies, which provides valuable “proof-of-principle” evidence to correlate experimental data with human physiology. This translational approach requires state-of-the art experimental and clinical facilities, as well as a broad network of pre-clinical and clinical collaborators.

Dr. Börgeson trained at Linköping University in Sweden, University College Dublin in Ireland, and the University of California San Diego in USA, before joining Gothenburg University in 2016. Her research resulted in numerous publications in top journals. In addition, Dr. Börgeson received several awards in recognition of her scientific work, including the VR and SSMF establishment award and several Young Investigator and Emerging Leader Awards.

National and International Collaborations

The Börgeson laboratory collaborates with several clinical platforms in Gothenburg, including Dr. Ville Wallenius and Dr. Lars Fändriks at the Department of Surgery, Sahlgrenska Hospital, as well as the “Surgical Oncology Laboratory” and the “Fibrinolys Laboratory”. At the Wallenberg Laboratory, Dr Börgeson collaborates with leading Swedish scientists Dr. Jan Borén and Dr. Fredrik Bäckhed. Other national collaborations are established with Dr. Lena Jonasson and Dr. Robert Blomgran at the University of Linköping, as well as research staff at Uppsala University and the SciLifeLab national resource for molecular biosciences.

In addition, Dr. Börgeson has several international collaborations with leading scientists in the field. These include the University of California San Diego, University of California Davis, University College Dublin and the University College London.

Dr. Börgeson was recently awarded a Pilot Project Grant from the National Institutes of Health, in collaboration with Dr. Lange at UC San Diego. This pilot project established a collaboration with the West Coast Metabolomics Center at UC Davis, to investigate changes to the lipid metabolome in patient plasma samples.

Research Opportunities in the Laboratory

​We are currently recruiting post-docs, PhD students, registered nurses and lab technicians. For more information please contact emma.borgeson@gu.se

Emma Börgeson
Photo: Cecilia Hedström
Contact Information

Emma Börgeson

Wallenberglaboratoriet, Sahlgrenska University Hospital Blå Stråket 5, 413 45, Gothenburg

Visiting Address:
Sahlgrenska University Hospital Blå Stråket 5, Elevator H, level 2/3

Delivery address:
Wallenberglaboratoriet, Lab 7, Bruna Stråket 16, 413 45 Göteborg, Sweden

+46 31 342 38 33 (office)
+46 31 342 94 83 (lab)

emma.borgeson@gu.se

Video (04:03)
Börgeson Lab

Group Members

Catherine Åhlund

Biomedical analysist, University of Gothenburg

Ida Bergström, PhD

Flow cytometry coordinator
Clinical Immunology Department

Matúš Soták, PhD

Postdoctoral Fellow

Postdoctoral Fellow, AstraZeneca, Sweden.
PhD in Physiology, Faculty of Science, Charles University in Prague, Czech Republic.
MSc Biology – Cell biology and biochemistry, Charles University in Prague, Czech Republic.  

Meenu Rohini Rajan, PhD

Postdoctoral Fellow

PhD in Medicine Linköping University, Sweden.
MSc in Genetic Manipulation and Molecular Cell Biology, University of Sussex, UK

Jamie Kraft

PhD Student, University of Gothenburg 

Alankrita Rani

Visiting student, University of Gothenburg 

Madison Clark

Visiting student

California State Polytechnic University, USA.

Armando Vazques

Visiting student, University of California, San Diego

Alumni

David Tandio ​
Visiting student
University of Gothenburg 

Benuarda Toto
Graduate student
Technische Universität Dresden

Alexis (Lexi) Gauthier
BSc student
Oregon State University, USA.

Alexandra Ferraro Werling
BSc student
University of Gothenburg, Sweden.

Emelie Shehadeh
Undergraduate student 
University of Gothenburg

Research Summary

We are a translational research team, investigating the underlying disease mechanisms of obesity and cardiometabolic disease, with a special interest in inflammatory resolution.

Inflammation is a key driver of obesity-induced cardiometabolic pathophysiology. It is often forgotten that inflammation consists of two phases: the initial acute phase, followed by a resolving phase. In order for inflammation to subside, resolution must be actively induced by specialized pro-resolving lipid mediators (SPMs). These include the ω3-polyunsaturated fatty acids (PUFA)-derived protectins, resolvins and maresins, as well as the ω6-PUFA-derived LipoxinA4 (LXA4) and LipoxinB4 (LXB4). Lipoxins attenuate neutrophil recruitment and induce a pro-resolving M2 macrophage (MΦ) phenotype, which promotes efferocytosis, i.e. removal of apoptotic cells by phagocytes. LXA4 mediates protection mainly via the FPR2/ALX G-protein coupled receptor, while the LXB4 receptor is yet to be identified. Importantly, both ‘stop’ and ‘go’ signals are equally important for achieving adequate inflammatory response and any dysregulation may cause disease.

The overall aim of our research is to investigate and harness the therapeutic potential of lipoxins. Our studies suggest that treatment with lipoxins attenuates obesity-induced adipose inflammation and subsequent development of systemic disease (Börgeson et al, Cell Metabolism, 2015). We are currently investigating the underlying mechanisms that mediate this protection, and whether our results from preclinical models can be translated to human pathophysiology.

We combine experimental studies with clinical basic research to address our hypothesis in a translational manner. We use ex vivo cultures of tissue biopsies, which provide valuable "proof-of-principle" evidence to correlate our experimental data with human physiology. This translational approach requires state-of-the art experimental and clinical facilities, as well as a broad network of collaborators.

Key Publications

PubMed: Emma Börgeson

GUP Latest publications: Emma Börgeson

Meenu Rohin Rajan, Matus Sotak, Fredrik Barrenäs, Tong Shen, Kamil Borkowski, Nicholas J Ashton, Christina Biörserud, Tomas L Lindahl, Sofia Ramström, Michael Schöll et al.
Comparative analysis of obesity-related cardiometabolic and renal biomarkers in human plasma and serum.
Scientific reports Oct 28;9(1):15385. (2019) doi: 10.1038/s41598-019-51673-0.

Key original papers

Börgeson E, Wallenius V, Syed GH, Darshi M, Lantero Rodriguez J, Biörserud C, Ragnmark Ek M, Björklund P, Quiding-Järbrink M, Fändriks L, Godson C, Sharma K.
AICAR ameliorates high-fat diet-associated pathophysiology in mouse and ex vivo models, independent of adiponectin.
Diabetologia. 60(4):729-739 (2017). PMID: 28188334

Börgeson E, Johnsson A, Lee Y.S., Till A, Syed H, Ali-Shah, Guiry P, Dalli D, Colas R, Serhan CN, Godson C, Sharma K.
Lipoxin A4 attenuates obesity-induced adipose inflammation, liver and kidney disease.
Cell Metabolism. 7;22(1):125-37 (2015). PMID:26052006

Börgeson E, McGillicuddy FC, Harford KA, Corrigan N, Higgins DF, Maderna P, Roche HM, Godson C.
Lipoxin A4 attenuates adipose inflammation.
FASEB Journal. 26(10):4287-94 (2012). PMID: 22700871

Börgeson E, Docherty NG, Murphy M, Rodgers K, Ryan A, O'Sullivan TP, Guiry PJ, Goldschmeding R, Higgins DF, Godson C.
Lipoxin A4 and benzo-lipoxin A4 attenuate experimental renal fibrosis.
FASEB Journal. 25(9):2967-79. (2011). PMID: 21628447

Börgeson E, Lönn J, Bergström I, Brodin VP, Ramström S, Nayeri F, Särndahl E, Bengtsson T.
Lipoxin A4 inhibits porphyromonas gingivalis-induced aggregation and reactive oxygen species production by modulating neutrophil-platelet interaction and CD11b expression.
Infection and Immunity 79(4):1489-97. (2011). PMID: 21263017

Key review papers

Börgeson E.
The role of lipoxins in cardiometabolic physiology and disease.
Cardiovascular Endocrinology Journal, October 28, doi: 10.1097/XCE.0000000000000068. (2015).

Börgeson E, Sharma K.
Obesity, immunomodulation and chronic kidney disease.
Current Opinion in Pharmacol. 13(4):618-24. (2013). PMID: 23751262

Börgeson E, Godson C.
Resolution of inflammation: therapeutic potential of pro-resolving lipids in type 2 diabetes mellitus and associated renal complications.
Frontiers in Immunology, 18;3:318. (2012). PMID: 23087692

Grants and Awards

Active research grants as Principal Investigator

Institutional Support, University of Gothenburg

Completed research grants

  • Konrad och Helfrid Johansson’s Foundation (2016)
  • Marie Curie International Outgoing Fellowship (2012-2015) - Post-doctoral fellowship
  • IRCSET Embark Initiative (2007-2011) - PhD Scholarship
  • Goljas memorial grant (2015)
  • Wilhelm and Martina Lundgren’s grant (2015)
  • Anna Whitlock’s Memorial Foundation (2007)
  • Dr. Felix Neuberghs Foundation (2007)
  • Emil & Maria Palms Foundation (2007)
  • Filip Lundbergs Foundation (2007)

Awards

  • Award for women scientists nomination, Hasselblad Foundation, Sweden (2015 & 2017)
  • Junior Investigator AwardInternational Conference on Phospholipase A2 and Lipid Mediators, San Diego (2016)
  • Emerging Leaders Award in Nutritional Sciences, Experimental Biology, San Diego (2016)
  • Highlighted posterBioactive Lipids in Inflammation & Diseases, Puerto Rico (2013)
  • Roche National Researcher of the Year nomination, Ireland (2013)
  • Honorary Directors Prize due to special distinction, UCD Conway festival, Ireland (2013)
  • Best moderated poster, Diabetes & Vascular biology, UCD Conway festival, Ireland (2013)
  • Best scientific presentation, Irish Society of Nephrology, Ireland (2013)
  • Outstanding junior career progression, ERA-EDTA ‘Molecular Targets in Renal Disease’ Symposia, Germany (2011)

News and Media

In the Media

News Spotlight